Targovax to present at upcoming conferences

Oslo, 12 September 2022 – Targovax ASA announces that members of its executive management team are invited to present at upcoming conferences:

H.C. Wainwright 24th Annual Global Investment Conference, virtual
Date: 12 September 2022
Presenter: Erik Digman Wiklund, CEO
Time: Presentation available online from 07:00 EDT / 13:00 CEST

RAS Targeted Drug development summit, Boston
Date: 28 September 2022
Presenter: Lone Ottesen, CMO
Time: 12:30 EDT / 18:30 CEST

Immuno-Oncology Summit, Boston
Date: 14 October 2022
Presenter: Erik Digman Wiklund, CEO
Time: 11:45 EDT / 17:45 CEST

World Vaccine Congress Europe, Barcelona
Date: 11-14 October 2022
Presenter: Lubor Gaal, CFO
Time: TBD


For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@targovax.com

Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com

Media enquires:
Andreas Tinglum – Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no

About Targovax

Activating the patient’s immune system to fight cancer

Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors. Targovax’s focus is to activate the patient’s immune system to fight cancer, and thereby bring benefit to cancer patients with few available treatment alternatives. Targovax is assessing its product candidates in different cancer indications, including melanoma, mesothelioma and multiple myeloma, and has demonstrated a favorable safety and tolerability profile.

Targovax’s lead clinical candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to selectively infect cancer cells and activate the immune system against the tumor. Following very encouraging clinical data in several indications, both as monotherapy and in combinations, ONCOS-102 is progressing into a randomized phase 2 trial in melanoma patients resistant to PD-1 checkpoint inhibitor treatment.

Building on successful studies demonstrating clinical efficacy and providing deep mechanistic insights, the Targovax platform is being expanded into delivery of circular RNA (circRNA). In addition, Targovax has a KRAS immunotherapy program, with lead cancer vaccine candidate, TG01, due to enter the clinic in the second half of 2022. This provides Targovax with a rich pipeline of innovative future immunotherapy product candidates to follow ONCOS-102.